The PRF Lonafarnib Pre-Clinical Drug Supply Program Material

To the extent that PI and Recipient wish to renew this agreement, they may so apply, and PRF reserves the right to approve or deny such renewal application. 3. [...] PRF Lonafarnib Pre-clinical Drug Supply Program MTA Non-Gov't June 2024 Page 2 of 4 PI and Recipient acknowledge that the breach of any provision contained in Paragraph 4 shall constitute a material breach of this agreement, and that PRF shall be entitled to seek an injunction to prevent or remedy any such breach. [...] PI and Recipient agree that they will not administer the Compound, either directly or indirectly, to humans in any manner or form whatsoever. 11. [...] PI and Recipient represent and warrant that they are regularly engaged in conducting tests in vitro or in laboratory research animals and are qualified by training and/or experience to conduct such tests on the Compound.PRF Lonafarnib Pre-clinical Drug Supply Program MTA Non-Gov't June 2024 Page 3 of 4 12. [...] PI and Recipient represent and warrant that they have adequate facilities for the investigation of the Compound. 13. [...] PI and Recipient represent and warrant that they will use the Compound for Research only and not for any other purpose, including the development of any commercial product containing the Compound, including but limited to analogues or derivatives thereof, or for Research conducted on another party’s behalf. 14. [...] PI and Recipient acknowledge and agree that the Compound is experimental in nature and may have unknown hazardous characteristics, and that they are aware of the risks of working with experimental compounds. 15. [...] PI and Recipient agree that they shall not chemically modify the Compound. [...] PI and Recipient agree that they shall immediately cease use of the Compound and shall return any unused supply of Compound to Entity upon Entity’s request, if Sentynl terminates their agreement with PRF. 18. [...] PI and Recipient shall grant Sentynl third-party beneficiary rights to enforce the terms and conditions of this Agreement against them. 21.